viewOpyl Ltd

Shareroot appoints new chairman to advance digital health focus

Incoming chairman Dr Julian Chick has more than 25 years of experience in the biotechnology and medical technology industries.

board table
Dr Chick has led both public and private companies

Shareroot Ltd (ASX:SRO) has appointed Dr Julian Chick as chairman, effective May 6 2019, following the resignation of Harvey Kaplan.

Kaplan was appointed in an interim capacity until a suitable chair could be identified and has been pivotal in realigning the company and charting its path forward.

Rebuilding the foundation and recalibrating the strategic direction of the company over the past three months has required a considerable effort from the ShareRoot board, led by Kaplan and newly appointed CEO, Michelle Gallaher.

READ: ShareRoot to turn focus on opportunity in healthcare sector

Finding an appropriately qualified and experienced chairman to advance the digital health focus of the company has been one of the organisations most important priorities.

Dr Julian Chick is an executive with more than 25 years of experience in the biotechnology and medical technology industry as well as five years in investment banking.

Having led both public and private companies, Dr Chick’s previous roles include investment adviser, healthcare analyst for private equity investors, portfolio manager, investment banker and venture capitalist.

READ: ShareRoot receives funding from European parliament member

Dr Chick has background with ShareRoot, as a shareholder and later working as an independent advisor on The Social Science transaction in April 2018 and more recently in the development of the Media Consent Medical functionality and market entry plan with Michelle Gallaher, ShareRoot CEO, over the past six months.

Gallaher said: “We are really delighted and fortunate to welcome Dr Chick to the board.

“Gaining access to Dr Chick’s investor network and know-how as well as his deep health technology development skills is a significant win for the company.”

Quick facts: Opyl Ltd

Price: 0.1 AUD

Market: ASX
Market Cap: $2.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...



Ludomade has already closed its first major deal under the ShareRoot umbrella

ShareRoot (ASX:SRO) CEO Noah Abelson-Gertler speaks to Proactive Investors about the addition of a fourth revenue stream through the acquisition of Ludomade Inc, the new brands that have signed on to the beta testing program for the MediaConsent platform that is now past the halfway point,...

on 11/29/2018

2 min read